Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial-Reference-Cited by-同舟云学术

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

Published:2010-01 Issue:1 Volume:62 Page:222-233
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Merrill Joan T.,Neuwelt C. Michael,Wallace Daniel J.,Shanahan Joseph C.,Latinis Kevin M.,Oates James C.,Utset Tammy O.,Gordon Caroline,Isenberg David A.,Hsieh Hsin-Ju,Zhang David,Brunetta Paul G.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.27233/fullpdf

Reference48 articles.

1. Diagnosis of systemic lupus erythematosus;Gill;Am Fam Physician,2003

2. Systemic lupus erythematosus;Rahman;N Engl J Med,2008

3. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus;Stoll;Br J Rheumatol,1996

4. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans;Dooley;Kidney Int,1997

5. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage;Alarcon;Rheumatology (Oxford),2004

Cited by 1091 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B cells and generation of antibodies;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Management of lupus nephritis;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. Targeted therapies in SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

4. Clinical markers, metrics, indices, and clinical trials;Dubois' Lupus Erythematosus and Related Syndromes;2025

5. The musculoskeletal system and bone metabolism;Dubois' Lupus Erythematosus and Related Syndromes;2025